Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325599 | 0.88 | NPC1 (0.51) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL10867808 | 0.88 | GAA (0.43) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL6483278 | 0.84 | MAPT (0.55) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL9507972 | 0.84 | SMN1; SMN2 (0.49) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL9509188 | 0.84 | RAB9A (0.54) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL9692781 | 0.84 | KDM4C (0.37) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL7016502 | 0.81 | SMN1; SMN2 (0.60) | RAB9ANPC1SMN1; SMN2TP53KDM4E | |
| SCHEMBL6480385 | 0.81 | ALDH1A1 (0.40) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL6475609 | 0.80 | ATP4A (0.50) | GAARAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL7289169 | 0.80 | RAB9A (0.46) | GAARAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7785630-B2 | Preparation and administration form comprising an acid-labile active compound | NYCOMED GMBH (DE) | 2010-08-31 | — | — | US | claimed |
| WO-2006086978-A2 | USE OF DEUTERATED N-[2-(5-METHOXY-1H-INDOL-3-YL)-ETHYL]ACETAMIDES AND THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, AND MEDICAMENTS CONTAINING SAID COMPOUNDS | BIRDS PHARMA GMBH BEROLINA INNOVATIVE RESEARCH & DEVELOPMENT SERVICES (DE) | 2006-08-24 | — | — | WO | claimed |
| EP-4072532-B1 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | EVONIK OPERATIONS GMBH (DE) | 2024-01-24 | — | — | EP | disclosed |
| US-11730708-B2 | Dosage form for use in treating or preventing of a disease | EVONIK OPERATIONS GMBH (DE) | 2023-08-22 | — | — | US | disclosed |
| US-20230048354-A1 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | EVONIK OPERATIONS GMBH (DE) | 2023-02-16 | — | — | US | disclosed |
| US-20230012981-A1 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | EVONIK OPERATIONS GMBH (DE) | 2023-01-19 | — | — | US | disclosed |
| CN-114786652-A | Dosage forms for treating or preventing diseases | 赢创运营有限公司 | 2022-07-22 | — | — | CN | disclosed |
| WO-2021115650-A1 | DOSAGE FORM FOR USE IN TREATING OR PREVENTING OF A DISEASE | EVONIK OPERATIONS GMBH (DE) | 2021-06-17 | — | — | WO | disclosed |
| EP-2112920-B1 | PROTON PUMP-INHIBITOR-CONTAINING CAPSULES WHICH COMPRISE SUBUNITS DIFFERENTLY STRUCTURED FOR A DELAYED RELEASE OF THE ACTIVE INGREDIENT | INTELLIPHARMACEUTICS CORP (CA) | 2018-07-25 | — | — | EP | disclosed |
| US-9636306-B2 | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient | INTELLIPHARMACEUTICS CORP. (CA) | 2017-05-02 | — | — | US | disclosed |
| US-20160324723-A1 | PHARMACEUTICAL PRODUCT FOR INJECTION | TAKEDA GMBH (DE) | 2016-11-10 | — | — | US | disclosed |
| US-6328993-B1 | Oral administration form for an acid liable active proton pump inhibitor | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 2001-12-11 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0218336-B1 | USE OF BENZYLSULFINYLBENZIMIDAZOLES AS CYTOPROTECTIVE AGENTS FOR THE GASTROINTESTINAL TRACT | NIPPON CHEMIPHAR CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4721718-A | 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers | G. D. SEARLE & CO. (US) | 1988-01-26 | — | — | US | disclosed |
| US-4687775-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1987-08-18 | — | — | US | disclosed |
| EP-0218336-A2 | Use of benzylsulfinylbenzimidazoles as cytoprotective agents for the gastrointestinal tract | NIPPON CHEMIPHAR CO., LTD. (JP) | 1987-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | GAA 160/4885RAB9A 486/4885NPC1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.